Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.99 USD | -0.40% | -0.64% | -16.11% |
Apr. 25 | Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors | CI |
Apr. 17 | TD Cowen Cuts Price Target on Franklin Resources to $29 From $30 | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12.21 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.11% | 13.16B | C+ | ||
-6.44% | 88.47B | C- | ||
+15.32% | 84.55B | C+ | ||
+12.36% | 26.01B | B- | ||
-6.65% | 17.28B | - | B+ | |
+6.74% | 14.28B | B | ||
+16.00% | 9.52B | B | ||
+26.11% | 8.75B | C- | ||
+27.22% | 7.13B | - | - | |
+7.48% | 5.32B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BEN Stock
- Ratings Franklin Resources, Inc.